Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer

A randomized clinical trial

Pierluigi Benedetti Panici, Angelo Maggioni, Neville Hacker, Fabio Landoni, Sven Ackermann, Elio Campagnutta, Karl Tamussino, Raimund Winter, Antonio Pellegrino, Stefano Greggi, Roberto Angioli, Natalina Manci, Giovanni Scambia, Tiziana Dell'Anna, Roldano Fossati, Irene Floriani, Rita S. Rossi, Roberto Grassi, Giuseppe Favalli, Francesco Raspagliesi & 3 others Diana Giannarelli, Luca Martella, Costantino Mangioni

Research output: Contribution to journalArticle

312 Citations (Scopus)

Abstract

Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95% confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6% in the systematic lymphadenectomy and control arms, respectively (difference = 9.6%, 95% CI = 1.5% to 21.6%), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95% CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95% CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47%, respectively (difference = 1.5%, 95% CI = -8.4% to 10.6%), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95% CI = -11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P

Original languageEnglish
Pages (from-to)560-566
Number of pages7
JournalJournal of the National Cancer Institute
Volume97
Issue number8
DOIs
Publication statusPublished - Apr 20 2005

Fingerprint

Lymph Node Excision
Ovarian Neoplasms
Randomized Controlled Trials
Confidence Intervals
Disease-Free Survival
Survival Rate
Recurrence
Survival
Gynecology
Blood Transfusion
Obstetrics
Regression Analysis
Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer : A randomized clinical trial. / Panici, Pierluigi Benedetti; Maggioni, Angelo; Hacker, Neville; Landoni, Fabio; Ackermann, Sven; Campagnutta, Elio; Tamussino, Karl; Winter, Raimund; Pellegrino, Antonio; Greggi, Stefano; Angioli, Roberto; Manci, Natalina; Scambia, Giovanni; Dell'Anna, Tiziana; Fossati, Roldano; Floriani, Irene; Rossi, Rita S.; Grassi, Roberto; Favalli, Giuseppe; Raspagliesi, Francesco; Giannarelli, Diana; Martella, Luca; Mangioni, Costantino.

In: Journal of the National Cancer Institute, Vol. 97, No. 8, 20.04.2005, p. 560-566.

Research output: Contribution to journalArticle

Panici, PB, Maggioni, A, Hacker, N, Landoni, F, Ackermann, S, Campagnutta, E, Tamussino, K, Winter, R, Pellegrino, A, Greggi, S, Angioli, R, Manci, N, Scambia, G, Dell'Anna, T, Fossati, R, Floriani, I, Rossi, RS, Grassi, R, Favalli, G, Raspagliesi, F, Giannarelli, D, Martella, L & Mangioni, C 2005, 'Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial', Journal of the National Cancer Institute, vol. 97, no. 8, pp. 560-566. https://doi.org/10.1093/jnci/dji102
Panici, Pierluigi Benedetti ; Maggioni, Angelo ; Hacker, Neville ; Landoni, Fabio ; Ackermann, Sven ; Campagnutta, Elio ; Tamussino, Karl ; Winter, Raimund ; Pellegrino, Antonio ; Greggi, Stefano ; Angioli, Roberto ; Manci, Natalina ; Scambia, Giovanni ; Dell'Anna, Tiziana ; Fossati, Roldano ; Floriani, Irene ; Rossi, Rita S. ; Grassi, Roberto ; Favalli, Giuseppe ; Raspagliesi, Francesco ; Giannarelli, Diana ; Martella, Luca ; Mangioni, Costantino. / Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer : A randomized clinical trial. In: Journal of the National Cancer Institute. 2005 ; Vol. 97, No. 8. pp. 560-566.
@article{9283eb78bebf4f92a82653690bd45ef4,
title = "Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: A randomized clinical trial",
abstract = "Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95{\%} confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6{\%} in the systematic lymphadenectomy and control arms, respectively (difference = 9.6{\%}, 95{\%} CI = 1.5{\%} to 21.6{\%}), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95{\%} CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95{\%} CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47{\%}, respectively (difference = 1.5{\%}, 95{\%} CI = -8.4{\%} to 10.6{\%}), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95{\%} CI = -11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P",
author = "Panici, {Pierluigi Benedetti} and Angelo Maggioni and Neville Hacker and Fabio Landoni and Sven Ackermann and Elio Campagnutta and Karl Tamussino and Raimund Winter and Antonio Pellegrino and Stefano Greggi and Roberto Angioli and Natalina Manci and Giovanni Scambia and Tiziana Dell'Anna and Roldano Fossati and Irene Floriani and Rossi, {Rita S.} and Roberto Grassi and Giuseppe Favalli and Francesco Raspagliesi and Diana Giannarelli and Luca Martella and Costantino Mangioni",
year = "2005",
month = "4",
day = "20",
doi = "10.1093/jnci/dji102",
language = "English",
volume = "97",
pages = "560--566",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer

T2 - A randomized clinical trial

AU - Panici, Pierluigi Benedetti

AU - Maggioni, Angelo

AU - Hacker, Neville

AU - Landoni, Fabio

AU - Ackermann, Sven

AU - Campagnutta, Elio

AU - Tamussino, Karl

AU - Winter, Raimund

AU - Pellegrino, Antonio

AU - Greggi, Stefano

AU - Angioli, Roberto

AU - Manci, Natalina

AU - Scambia, Giovanni

AU - Dell'Anna, Tiziana

AU - Fossati, Roldano

AU - Floriani, Irene

AU - Rossi, Rita S.

AU - Grassi, Roberto

AU - Favalli, Giuseppe

AU - Raspagliesi, Francesco

AU - Giannarelli, Diana

AU - Martella, Luca

AU - Mangioni, Costantino

PY - 2005/4/20

Y1 - 2005/4/20

N2 - Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95% confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6% in the systematic lymphadenectomy and control arms, respectively (difference = 9.6%, 95% CI = 1.5% to 21.6%), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95% CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95% CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47%, respectively (difference = 1.5%, 95% CI = -8.4% to 10.6%), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95% CI = -11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P

AB - Background: The role of systematic aortic and pelvic lymphadenectomy in patients with optimally debulked advanced ovarian cancer is unclear and has not been addressed by randomized studies. We conducted a randomized clinical trial to determine whether systematic aortic and pelvic lymphadenectomy improves progression-free and overall survival compared with resection of bulky nodes only. Methods: From January 1991 through May 2003, 427 eligible patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIB-C and IV epithelial ovarian carcinoma were randomly assigned to undergo systematic pelvic and para-aortic lymphadenectomy (n = 216) or resection of bulky nodes only (n = 211). Progression-free survival and overall survival were analyzed using a log-rank statistic and a Cox multivariable regression analysis. All statistical tests were two-sided. Results: After a median follow-up of 68.4 months, 292 events (i.e., recurrences or deaths) were observed, and 202 patients had died. Sites of first recurrences were similar in both arms. The adjusted risk for first event was statistically significantly lower in the systematic lymphadenectomy arm (hazard ratio [HR] = .75, 95% confidence interval [CI] = 0.59 to 0.94; P = .01) than in the no-lymphadenectomy arm, corresponding to 5-year progression-free survival rates of 31.2 and 21.6% in the systematic lymphadenectomy and control arms, respectively (difference = 9.6%, 95% CI = 1.5% to 21.6%), and to median progression-free survival of 29.4 and 22.4 months, respectively (difference = 7 months, 95% CI = 1.0 to 14.4 months). The risk of death was similar in both arms (HR = 0.97, 95% CI = 0.74 to 1.29; P = .85), corresponding to 5-year overall survival rates of 48.5 and 47%, respectively (difference = 1.5%, 95% CI = -8.4% to 10.6%), and to median overall survival of 58.7 and 56.3 months, respectively (difference = 2.4 months, 95% CI = -11.8 to 21.0 months). Median operating time was longer, and the percentage of patients requiring blood transfusions was higher in the systematic lymphadenectomy arm than in the no-lymphadenectomy arm (300 versus 210 minutes, P

UR - http://www.scopus.com/inward/record.url?scp=20244376152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20244376152&partnerID=8YFLogxK

U2 - 10.1093/jnci/dji102

DO - 10.1093/jnci/dji102

M3 - Article

VL - 97

SP - 560

EP - 566

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 8

ER -